NIS793
NIS793 is a drug used to treat Metastatic Pancreatic Ductal Adenocarcinoma, Myelofibrosis, Breast Cancer, and other conditions. NIS793 is being actively studied in 5 studies and prior, has been studied in 1.
| Top Sponsors | Top Sites | Top Investigators |
|---|---|---|
| Novartis Pharmaceuticals | Novartis Investigative Site | |
| Beth Israel Deaconess Medical Cente | ||
| Emory University School of Medicine/Winship Cancer Institute |
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED
N
Recruiting
- Metastatic Colorectal Cancer
- NIS793
- +4 more
- Brno, Czech Republic, Czechia
- +8 more
2022-02-22
Feb 22, 2022N
Phase I/Ib Study of NIS793 in Combination With PDR001 in Patients With Advanced Malignancies. - 2021
Completed
- Breast Cancer
- +5 more
- NIS793
- PDR001
- Nashville, Tennessee
- +11 more
2022-01-28
Jan 28, 2022N
Recruiting
- Metastatic Pancreatic Ductal Adenocarcinoma
- NIS793
- +3 more
- Fayetteville, Arkansas
- +16 more
2022-02-01
Feb 1, 2022N
N
Recruiting
- Metastatic Pancreatic Ductal Adenocarcinoma
- NIS793
- +3 more
- Atlanta, Georgia
- +29 more
2022-02-21
Feb 21, 2022N
N
Recruiting
- Myelofibrosis
- Ruxolitinib
- +5 more
- Adelaide, South Australia, Australia
- +33 more
2022-01-31
Jan 31, 2022